Home/Divamics/Wenlang Liu

WL

Wenlang Liu

Director, Computational Chemistry

Therapeutic Areas

Immunology Metabolic

Divamics Pipeline

Drug	Indication	Phase
DVI-001	Inflammatory Bowel Disease	Preclinical
DVI-002	Inflammatory Bowel Disease	Preclinical
DVI-003	Diabetes and Obesity	Preclinical
DVI-004	Metabolic Disease	Preclinical

Leadership Team at Divamics

John Zheng, PhD

Founder & Chief Executive Officer

Co-Founder & Chief Scientific Officer

Jinbo Yang, DBA

Co-Founder & Chief Financial Officer

Director, Medicinal Chemistry

Director, Business Development

View full Divamics profile